Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic eq...
Dr. Reddy’s Lab (NYSE:RDY +1.8%)announced on Friday the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of Eli Lilly's (LLY) cancer drug, Alimta, in the U.S. The Alimta brand and generic had U.S. sales of about $1.24B for the most recent ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg...
Dr. Reddy's Laboratories Limited (RDY) Q4 2022 Earnings Conference Call May 19, 2022 08:00 ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Gunupati Prasad - Co-Chairman & Managing Director Erez Israeli - Chief Executive Officer Parag Agarwal - Chi...
Dr. Reddy's press release (NYSE:RDY): Q4 GAAP EPS of $0.07. Revenue of $717M (+11.0% Y/Y) beats by $54.69M. For further details see: Dr. Reddy's GAAP EPS of $0.07, revenue of $717M beats by $54.69M
BJ, CAE, CAN, DESP, EXP, GOGL, GOOS, GRAB, KSS, LSPD, NGG, NM, NNOX, PLCE, RDY, VIPS, WMS, OTCPK:XIACF For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Posaconazole Delayed-Release Tablets, 100 mg, the therapeutic generic equiv...
Dr. Reddy’s Laboratories (NYSE:RDY) launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL, in the U.S. market. The medicine is used to treat several conditions including arthritis, blood disorders and severe allergic reactions. SOLU-MEDR...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equival...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...